Stemtech acquires Seacret Direct/Viago for $32.5M in stock via merger agreement

Stemtech Corp

Merger agreement executed December 2, 2024; Seacret Direct/Viago to merge into Stemtech.
Total consideration of $32.5 million paid in Stemtech common stock.
Both companies operate in the health and wellness space; deal expected to benefit shareholders.
No premium or financial details disclosed; closing conditions not specified.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.